key: cord-0705481-aoa0cplg
authors: Scorza, Fulvio A; Finsterer, Josef
title: Asymptomatic SARS-CoV-2 infection complicated by acute, motor and sensory, axonal neuropathy (AMSAN)
date: 2021-10-12
journal: Clin Neurol Neurosurg
DOI: 10.1016/j.clineuro.2021.106975
sha: 926a8024fa9217e3592e61d26e32bee06d01ce7e
doc_id: 705481
cord_uid: aoa0cplg

nan

Journal Pre-proof Asymptomatic This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

To the Editor We read with interest the article by d'Orsi et al. about a 62 years-old male wo was diagnosed with SARS-CoV-2 associated Guillain-Barre syndrome (GBS) in the absence of symptoms of the COVID-19 infection [1] . It was concluded that neurologists should stay alert for neurological complications of SARS-CoV-2 infections even if the viral infection remains asymptomatic [1] . The study is appealing but raises concerns and comments. SARS-CoV-2 associated GBS in the absence of clinical manifestations of COVID-19 is not unusual. In a recent review of 220 patients with SARS-CoV-2 associated GBS [2] , six patient developed GBS prior to onset of COVID-19 [2] . Though we agree that the patient did not have subjective symptoms, the SARS-CoV-2 infection nonetheless caused abnormal laboratory parameters. Thus, the patient was asymptomatic in a narrow sense but symptomatic in a wider sense. Though the patient was diagnosed with an asymptomatic SARS-CoV-2 infection, he nonetheless received hydroxy-chloroquine, and tocilizumab [1] . The rationale for applying these drugs to an asymptomatic patient should be explained. Chloroquine and tocilizumab are not only ineffective for the treatment of COVID-19, they are both potentially neurotoxic. Thus, it cannot be excluded that they contributed to the damage of nerve roots respectively the peripheral nerves. From chloroquine it is known that it may not only be myotoxic but may also cause neuropathy in some cases [3] . From tociliczumab it is known that it may cause peripheral neuropathy in some cases [4] . A causal relation between the SARS-CoV-2 infection and GBS remains unproven. Since the index patient did not undergo detailed investigations of immunological parameters in the CSF it remains unclear if SARS-CoV-2 was truly responsible. From a previous study it is known that cytokines are typically elevated n the cerebro-spinal fluid (CSF) in SARS-CoV-2 associated GBS [4gigli]. Cytokines typically elevated in SARS-CoV-2 associated GBS include interleukin (IL)-6, IL-8, IL-1b and TNF-alpha. [5] . We propose to retest the CSF for the cytokine profile if material of the spinal tap is still available. Missing is which subtype of GBS was diagnosed in the index patient. Since the patient had developed motor and sensory disturbances and since nerve conduction studies (NCSs) revealed and axonal lesion, we suppose that acute, motor and sensory axonal neuropathy (AMSAN) is the appropriate GBS subtype.

Overall, the interesting report has some limitations which challenge the results and their interpretation. The infection with SARS-CoV-2 should be classified rather as minimal symptomatic than as asymptomatic, the cytokine profile in the CSF should be determined, the GBS subtype should be provided, and the neurotoxicity of tocizlizumab and hydroxy-chloroquine should be considered as contributing factor.

CoV-2 infection complicated by acute, motor and sensory, axonal neuropathy (AMSAN) Short title: GBS in an asymptomatic COVID-19 patient

São Paulo, Brasil. scorza@unifesp.br, carlascorza.nexp@gmail.com

Guillain-Barré syndrome as only manifestation of COVID-19 infection

Guillain-Barre syndrome in 220 patients with COVID-19

Miopatía y neuropatía inducida por cloroquina: tetraparesia progresiva con arreflexia que simula una polirradiculoneuropatía. A propósito de dos casos [Chloroquine-induced myopathy and neuropathy: progressive tetraparesis with areflexia that simulates a polyradiculoneuropathy

A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of tocilizumab

HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome